fda compounding semaglutide warning november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Diabetes advocacy group discourages use

The EU agency estimated that this condition may affect 1 in 10,000 people taking semaglutides for at least one year

Severe, persistent upper abdominal pain, with or without vomiting, should prompt urgent medical assessment

Like it never will.' Kim explains in confessional that it's always 'so intense' with Kanye and that she has no interest in engaging in a public feud with him.' 'I feel like I have to do something especially when it involves other people and it hurts other people

Cardiovascular Benefits Both Ozempic and Wegovy have been shown to have positive effects on heart health

By the time you hit the one-month mark, you should start seeing some real progress

Whilst GLP-1 receptor agonists are not licensed specifically as antihypertensive agents in the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved several formulations for glycaemic control and weight management